Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation

Oncogene

Volumn 32, Issue 5, 2013, Pages 663-669

  Yang, H ^a,b   Liu, Y ^a   Bai, F ^c   Zhang, J Y ^a   Ma, S H ^a,b   Liu, J ^a   Xu, Z D ^a   Zhu, H G ^a   Ling, Z Q ^d   Ye, D ^a   Guan, K L ^a,e   Xiong, Y ^a,b,c  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d ZHEJIANG CANCER HOSPITAL   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 hydroxymethylation; cancer biomarker; DNA methylation; TET

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; 5 METHYLCYTOSINE; BIOLOGICAL MARKER; DIOXYGENASE; GENOMIC DNA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; TEN ELEVEN TRANSLOCATION PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CATALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ENGINEERING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LIVER CANCER; LUNG CANCER; MALE; MOUSE; NONHUMAN; OXIDATION KINETICS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

5-METHYLCYTOSINE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOSINE; DIOXYGENASES; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; HYDROXYLATION; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873411803     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.67     Document Type: Article

References (22)

1. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F et al. (2011a). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224: 334-343.
2. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F et al. (2011b). Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43: 1262-1265.
3. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
4. Delhommeau F, Dupont S, Della VV, James C, Trannoy S, Masse A et al. (2009). Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289-2301.
5. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
6. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG et al. (2011). Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2: 627-637.
7. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q et al. (2011). Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333: 1303-1307.
8. Hemerly JP, Bastos AU, Cerutti JM. (2010). Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol 163: 747-755.
9. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. (2010). Role of tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466: 1129-1133.
10. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA et al. (2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333: 1300-1303.
11. Jones PA, Baylin SB. (2007). The epigenomics of cancer. Cell 128: 683-692. (Pubitemid 46273572)
12. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. (2009). Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41: 838-842.
13. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066.
14. Mullighan CG. (2009). TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet 41: 766-767.
15. Murugan AK, Bojdani E, Xing M. (2010). Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 393: 555-559.
16. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
17. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J et al. (2011). Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 43: 1256-1261.
18. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
19. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930-935.
20. Wu SC, Zhang Y. (2010). Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 11: 607-620.
21. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17-30.
22. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P et al. (2009). Gliomaderived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324: 261-265.